What will 500 tiger coins get me?: the “manifesting” million dollar blanket/throw rug! Hint hint[Miser]
Moderna Doubles in a Day on mRNA Cancer Vaccine Data — Still Chaseable?
Moderna +176.97% to $174.38; Merck +12.60%. Their personalized mRNA cancer vaccine intismeran autogene plus Keytruda hit both survival endpoints in the Phase 3 INTerpath-001 melanoma trial — the platform's first Phase 3 oncology win. BofA took its target to $170 from $40, yet the 23-analyst consensus is still Hold at $78.78, most models unrevised. Shorts lost an estimated $4.8bn. Against that: full data unpublished, LTM revenue $2.23bn and falling 27.6%. Chase the platform, buy Merck for the royalty, or wait for the data?
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments